Investors in Globus Medical (NYSE:GMED) Have Seen Notable Returns of 58% Over the Past Year
Investors in Globus Medical (NYSE:GMED) Have Seen Notable Returns of 58% Over the Past Year
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can boost returns by picking market-beating companies to own shares in. To wit, the Globus Medical, Inc. (NYSE:GMED) share price is 58% higher than it was a year ago, much better than the market return of around 24% (not including dividends) in the same period. If it can keep that out-performance up over the long term, investors will do very well! The longer term returns have not been as good, with the stock price only 14% higher than it was three years ago.
現在投資者可以很容易地購買一個指數基金,回報大致與市場相匹配。但投資者可以通過挑選表現優於市場的公司來提高回報。例如,Globus Medical, Inc. (紐交所:GMED) 的股價比一年前上漲了58%,遠遠超過同期市場約24%的回報(不包括分紅派息)。如果它能在長期內保持這種超出表現,投資者將會非常成功!長期回報則沒有那麼好,股票價格比三年前僅上漲了14%。
Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.
讓我們看看更長期的基本面,看看它們是否與股東回報一致。
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
不可否認的是,市場有時是有效的,但價格並不總是反映基本的業務表現。通過比較每股收益(EPS)和股價變化,我們可以了解投資者對公司的態度是如何隨時間變化的。
Over the last twelve months, Globus Medical actually shrank its EPS by 56%.
在過去的十二個月裏,Globus Medical 實際上每股收益下降了56%。
Given the share price gain, we doubt the market is measuring progress with EPS. Indeed, when EPS is declining but the share price is up, it often means the market is considering other factors.
考慮到股價的上漲,我們懷疑市場在用每股收益來衡量進展。實際上,當每股收益下降而股價上漲時,通常意味着市場在考慮其他因素。
However the year on year revenue growth of 102% would help. Many businesses do go through a phase where they have to forgo some profits to drive business development, and sometimes its for the best.
然而,102%的年同比營業收入增長會有所幫助。許多企業在發展業務時會經歷一個階段,在這個階段他們不得不放棄一些利潤,有時這也是爲了更好的發展。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以在下面看到盈利和營業收入隨時間的變化(通過點擊圖片發現確切值)。

It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. You can see what analysts are predicting for Globus Medical in this interactive graph of future profit estimates.
值得注意的是,CEO的薪酬低於類似規模公司的中位數。但是,雖然CEO的薪酬值得關注,但更重要的問題是公司未來能否增長盈利。您可以在這個關於未來利潤預估的互動圖表中查看分析師對Globuse Medical的預測。
A Different Perspective
不同的視角
We're pleased to report that Globus Medical shareholders have received a total shareholder return of 58% over one year. That gain is better than the annual TSR over five years, which is 7%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 2 warning signs we've spotted with Globus Medical .
我們高興地報告,Globuse Medical的股東在一年內獲得了58%的總股東回報。這一收益優於五年內的年化總股東回報,後者爲7%。因此,近期對公司的情緒似乎是積極的。在最好的情況下,這可能暗示着一些真正的業務勢頭,意味着現在可能是深入研究的好時機。雖然考慮市場狀況對股價的不同影響非常值得,但還有其他因素更爲重要。爲此,您應該意識到我們發現的Globuse Medical的兩個警告信號。
Of course Globus Medical may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
當然,Globus Medical可能不是最適合買入的股票。所以你可能想查看這份免費的成長股票集合。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文中引用的市場回報反映了當前在美國交易所上市股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。
譯文內容由第三人軟體翻譯。